In:
Current Neuropharmacology, Bentham Science Publishers Ltd., Vol. 21, No. 2 ( 2023-02), p. 424-436
Kurzfassung:
Since the early clinical efficacy of antipsychotics has not yet been well perceived,
this study sought to decide whether the efficacy of antipsychotics at week 2 can predict subsequent responses at week 6 and identify how such predictive capacities vary among different antipsychotics
and psychotic symptoms. Methods: A total of 3010 patients with schizophrenia enrolled in a randomized controlled trial (RCT)
and received a 6-week treatment with one antipsychotic drug randomly chosen from five atypical antipsych otics
(risperidone 2-6 mg/d, olanzapine 5-20 mg/d, quetiapine 400-750 mg/d, aripiprazole 10-30 mg/d, and ziprasidone 80-160 mg/d) and two typical antipsychotics (perphenazine 20-60 mg/d and
haloperidol 6-20 mg/d). Early efficacy was defined as the reduction rate using the Positive and Negative Syndrome Scale (PANSS) total score at week 2. With cut-offs at 50% reduction, logistic regression,
receiver operating characteristic (ROC) and random forests were adopted. Results: The reduction rate of PANSS total score and improvement of psychotic symptoms at week 2
enabled subsequent responses to 7 antipsychotics to be predicted, in which improvements in delusions, lack of judgment and insight, unusual thought content, and suspiciousness/ persecution were endowed
with the greatest weight. Conclusions: It is robust enough to clinically predict treatment responses to antipsychotics at week 6
using the reduction rate of PANSS total score and symptom relief at week 2. Psychiatric clinicians had better determine whether to switch the treatment plan by the first 2 weeks. Clinical Trial Registration Number: This RCT was registered at the Chinese Clinical Trials Registry
Identifier: ChiCTR-TRC-10000934).
Materialart:
Online-Ressource
ISSN:
1570-159X
DOI:
10.2174/1570159X21666221118164612
Sprache:
Englisch
Verlag:
Bentham Science Publishers Ltd.
Publikationsdatum:
2023
ZDB Id:
2119376-9
Bookmarklink